Cenix BioScience this week announced that it will establish a new subsidiary to accelerate the firm's research and development capabilities in areas such as central nervous system-focused drug discovery and in vivo RNAi.
The subsidiary will be based in Belgium and reflects "a major growth and diversification initiative ongoing since 2008 to broaden the company's range of activities beyond [its core] cell-based RNAi services," Dresden, Germany-based Cenix said.
As reported by Gene Silencing News, the company disclosed in 2009 that it began expanding its operations to include contract-research work in animals and siRNA-delivery technology for both research and therapeutic applications (GSN 4/30/2009).